Skip to content
Review Open access

Signaling pathways in the pathogenesis of diabetic kidney disease (review)

Sep 2026 · Nephrology (Saint-Petersburg) · 0 citations · 58 references

TL;DR

An overview of the key signaling pathways and molecular mediators that underlie typical pathophysiological processes in diabetic kidney disease is presented and central role of transforming growth factor-beta in activating various signaling pathways is noted.

Abstract

Diabetic kidney disease (DKD) is widespread and poses a significant medical and social challenge. Routine DKD markers, such as albuminuria and glomerular filtration rate, do not always reflect the initial stages and progression of kidney damage. Current DKD treatments, including glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibition, retain high residual risks of progression to end-stage renal failure. Dissatisfaction with diagnostic and treatment results prompts attention to poorly controlled processes, including glucose toxicity, oxidative stress, immune-mediated inflammation, hypoxia, cell death, glomerulosclerosis, and tubulointerstitial fibrosis. This article presents an overview of the key signaling pathways and molecular mediators that underlie typical pathophysiological processes. Hyperglycemia is the primary trigger for DKD, and glucose toxicity is mediated through multiple signaling pathways. Local RAAS not only affects intraglomerular hemodynamics but also leads to inflammation via toll-like receptors, kinase/signal transducer and activator of transcription, and nuclear factor kappa B, leading to excessive accumulation of extracellular matrix and fibrosis. Interconnections between cascades at the onset and progression of DKD, their regulation by positive feedback, and the central role of transforming growth factor-beta in activating various signaling pathways have been noted. The resulting death signals, through activation of the Hippo, Notch, and Wnt/β-catenin pathways, trigger autophagy, cell senescence, apoptosis, and necrosis. Stress or cell death generates mediators and signaling pathways that create vicious cycles that contribute to the progression of chronic kidney disease. Understanding signaling pathways will catalyze a paradigm shift in DKD management – from monitoring progression to targeting disease mechanisms in individual patients and from standard treatment to personalized therapy.

Read PDF

Similar papers

Review Open access Aug 2026

Research Progress on the Pathogenesis and Chinese and Western Medicine Treatment of Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a common microvascular complication of diabetes and an important cause of chronic kidney disease progressing to kidney failure. Its onset and progression are not attributable to hyperglycemia alone, but rather to the combined effects of multiple factors, including disorders of glucose a...

Xiao-Duo Ai, Gen-Ping Lei · 0 citations
Review Open access Oct 2026

Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives

Diabetic kidney disease (DKD) is among the most common and severe microvascular complications of diabetes and represents a leading cause of end-stage renal disease (ESRD) worldwide. Currently, although strict glycemic and blood pressure control, together with the use of renin–angiotensin system inhibitors, sodium-gluco...

Xu-Hao Li, Ya-Miao Wu, Ye-Xuan Shi et al. · 0 citations
Review Sep 2026

Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes.

Investigating treatments for CKD possess anti-inflammatory properties that might contribute to their previously established clinical benefits, including renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocortico...

Katherine R. Tuttle, Mehmet Kanbay, Radica Z. Alicic et al. · 1 citation
Review Open access Aug 2026

Protease-activated receptor 1 in diabetes and its chronic complications: signaling mechanisms and emerging therapeutic advances

Diabetes mellitus (DM) is a systemic metabolic disorder characterized by chronic hyperglycemia, which can affect the kidneys, retina, peripheral nerves, and cardiovascular system, ultimately leading to multiple chronic complications. Protease-activated receptor 1 (PAR1) is a G protein-coupled receptor activated through...

Yan-Rui Wei, Bing Wang, Qiu-Yue Wang · 0 citations
Review Open access Sep 2026

Targeting immune-hemodynamic coupling in early diabetic kidney disease: Mechanisms, biomarkers, and therapeutic opportunities.

Current diagnostic criteria for diabetic kidney disease (DKD) rely on moderately increased albuminuria (formerly microalbuminuria) or a persistent decline in estimated glomerular filtration rate (eGFR), both of which appear well after disease initiation. Substantial injury accumulates earlier, during a clinically silen...

L. Tian, B. Zheng, Yan-Yu Pang et al. · 0 citations
Review Open access Sep 2026

The role of classical protein tyrosine phosphatases in diabetic kidney disease and therapeutic implications

Approximately one-third of people with diabetes have diabetic kidney disease (DKD), and DKD remains a leading cause of kidney failure in the United States. DKD is characterized by injury to the glomerular filtration barrier and renal tubulointerstitium, arising from complex and convergent metabolic, hemodynamic, and in...

Grace LeBleu, F. Haj · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.